|
|
CIDS, Thomson Building
Glasgow, G12 8QQ United Kingdom
phone:+ 44 (0) 208 901 6551
fax:(44) (0) 141 330 4888
|
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.xstalbio.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Formulation and stabilization technology for protein-based drugs. |
|
| Management |
| Marie-Claire Parker (CEO), Co-founder and co-inventor of the PCMC technology; Barry D. Moore (Chief Scientist), Co-founder and co-inventor of the XstalBio PCMC technology; Mike Billingham (Business Development); John M Preston BVMS, PhD, MRCVS (Non-executive Director); Frank Colhoun, Company Secretary and CFO |
| |
|
|
| |
|
| Keywords |
| drug delivery, pharmaceuticals, proteins, formulation, stabilization, biomolecules, DrugDelivery |
|
|
|
| Description |
|
XstalBio has developed proprietary formulation and stabilization technology for protein-based drugs. |
|
| Technology / Differentiation |
| XstalBio's formulation and stabilization technology can be applied to the delivery of biomolecules via a number of routes, including pulmonary, parenteral and preparation as high concentration suspensions. The technology works with proteins, peptides, DNA, RNA and also small molecules. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members